Reach Us +1-504-608-2390
Recombinatory Hemagglutinin In Mammalian Cells For Vaccine Production | 11207
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

7th International Congress on Infectious Diseases

Berlin, Germany

4th International Conference on Mass Spectrometry

Milan, Italy
Share This Page

Recombinatory hemagglutinin in mammalian cells for vaccine production

2nd International Conference on Clinical & Cellular Immunology

Jiansong Tong

Accepted Abstracts: J Clin Cell Immunol

DOI: 10.4172/2155-9899.S1.015

Influenza hemagglutinin (HA) is an antigenic glycoprotein presented on the surface of virus and plays critical roles for the entry of virus into the cell. It has been implied as a primary target to produce neutralizing antibodies to prevent the viral infection. Although approved by US Food and Drug Administration, the current production process for the three vaccines takes about 6 months and their antigenic compositions must be modified annually. Therefore, multiple attempts have been described to develop novel methods to replace the traditional vaccine production technology. One of the studies that has been proved as safe and efficient on clinical trials is to directly inject recombinatory HA (rHA) into human subjects to produce neutralizing antibodies. However, the rHA used in those studies were purified from insect expression systems rather than mammalian cells. Here, we used different expression vectors trying to over express rHA in mammalian cells. Both western blots and fluorescence imaging data suggested only very few amounts of rHA expressed in cells by common vectors pcDNA3.1 and gateway destination vector pDEST40. However, rHA can be greatly over expressed in mammalian cells when HA was constructed into lentiviral vector. Endo H assay and sucrose density gradient fractionation experiment confirmed rHA was folded and trafficked correctly in the cell. Furthermore, hemadsorption assay verified the functionality of rHA. In summary, we built a stable mammalian cell line to successfully over express rHA that could be useful to produce influenza vaccine.
Jiansong Tong completed his Ph.D. from Department of Biochemistry, Biophysics and Molecular Biology at Iowa State University at Ames, Iowa USA. Currently, he is a research associate in Department of Cell Biology at The Scripps Research Institute at La Jolla, CA USA. He has published several papers in esteemed journals including PNAS, Nucleic Acids Res, JBC , and BMC Systems Biol etc. He has also served as an editorial board member for Journal of Clinical and Cellular Immunology since year 2010 and associate editor for Journal BMC Biotechnology from year 2013.